Gemeprost
| Clinical data | |
|---|---|
| Trade names | Cervagem |
| Other names | methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Pessary |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.058.869 |
| Chemical and physical data | |
| Formula | C23H38O5 |
| Molar mass | 394.552 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
- ^ "Cervagem 1 mg Pessary - Summary of Product Characteristics (SmPC)". (emc). 16 August 2019. Retrieved 7 September 2020.